SLU-PP-332 is an experimental synthetic small molecule developed through research associated with Saint Louis University and the Burris laboratory. It was designed as an agonist of the three estrogen-related receptors:
ERRα (ESRRA)
ERRβ (ESRRB)
ERRγ (ESRRG)
It has attracted attention because activation of ERR signaling can reproduce some molecular and metabolic adaptations normally associated with endurance exercise. This is why it is often informally called an “exercise mimetic.”
It is important not to confuse ERRs with the classical estrogen receptors ERα and ERβ. ERRs are a separate family of orphan nuclear receptors involved heavily in energy metabolism, mitochondrial function, and oxidative physiology.
Scientific classification
| Characteristic | SLU-PP-332 |
| Correct research name | SLU-PP-332 |
| “SLU-PP-332” | Commonly used but appears to be a name transposition |
| Chemical class | Synthetic small molecule |
| Drug class | Nuclear-receptor agonist |
| Primary targets | ERRα, ERRβ, ERRγ |
| Strongest activity | ERRα |
| Peptide? | No |
| Exercise mimetic? | Preclinical designation |
| Main research areas | Mitochondria, skeletal muscle, metabolism, obesity |
| Human clinical status | No established human clinical efficacy or safety data |
The original research characterized SLU-PP-332 as a pan-ERR agonist with somewhat greater potency toward ERRα and suitable pharmacokinetic properties for experimental use in mice.
1. Origin and development
SLU-PP-332 emerged from efforts to develop synthetic agonists capable of activating ERRs in vivo.
The rationale was based on an important observation: exercise causes major changes in skeletal-muscle gene expression, particularly genes involved in mitochondrial oxidative metabolism. ERRs are important transcriptional regulators of this program.
Researchers therefore asked whether pharmacologically activating ERRs could reproduce some of the metabolic effects of endurance exercise without requiring exercise itself.
The 2023 ACS Chemical Biology study reported the identification and characterization of SLU-PP-332 as a synthetic ERR pan-agonist.
A subsequent 2024 study investigated the molecule in mouse models of obesity and metabolic syndrome.
2. Mechanism of action
The central mechanism can be simplified as:
SLU-PP-332 → ERR activation → transcriptional metabolic program → mitochondrial/oxidative metabolism → increased fatty-acid utilization and energy expenditure
Step 1 — ERR activation
SLU-PP-332 activates ERRα, ERRβ and ERRγ.
These are nuclear receptors, meaning their activation ultimately influences gene transcription.
Step 2 — Interaction with metabolic transcriptional machinery
ERRs cooperate extensively with transcriptional regulators such as PGC-1α, which is strongly associated with exercise-induced mitochondrial adaptation.
The resulting transcriptional program affects genes involved in:
- mitochondrial biogenesis/function
- oxidative phosphorylation
- fatty-acid oxidation
- respiratory metabolism
- skeletal-muscle oxidative capacity
Step 3 — Increased oxidative metabolism
The experimental consequence is a shift toward greater use of oxidative metabolism and fatty acids.
In skeletal-muscle cells, SLU-PP-332 increased mitochondrial function and cellular respiration.
Step 4 — Skeletal-muscle adaptation
In mice, treatment increased the proportion of type IIa oxidative muscle fibers and improved exercise endurance.
Thus, the compound does not literally reproduce every physiological component of exercise. Rather, it activates some of the transcriptional/metabolic programs associated with endurance exercise.
3. Why is it called an “exercise mimetic”?
This term needs careful interpretation.
Normal endurance exercise produces many adaptations:
- increased mitochondrial capacity
- increased fatty-acid oxidation
- improved cardiovascular function
- neuromuscular adaptations
- improved insulin sensitivity
- skeletal-muscle remodeling
- vascular adaptation
- hormonal and inflammatory changes
SLU-PP-332 primarily attempts to reproduce a subset of the molecular metabolic program, particularly the ERR-dependent component.
The original animal work showed increased oxidative skeletal-muscle characteristics and enhanced endurance, which led to the exercise-mimetic description.
Therefore:
SLU-PP-332 is better described as an ERR-pathway exercise mimetic, rather than a pharmacological replacement for exercise.
4. Effects demonstrated in experimental models
A. Mitochondrial function
One of the strongest findings is its effect on mitochondrial metabolism.
In skeletal-muscle cells, SLU-PP-332 increased:
- mitochondrial function
- cellular respiration
- oxidative metabolism
These effects fit its ERR-mediated mechanism.
B. Skeletal-muscle oxidative fibers
Animal experiments demonstrated an increase in type IIa oxidative skeletal-muscle fibers.
This is relevant because oxidative fibers are better adapted to sustained aerobic metabolism than highly glycolytic muscle fibers.
C. Exercise endurance
Mice receiving SLU-PP-332 demonstrated enhanced exercise endurance.
This is one of the findings behind the compound’s popularity in exercise-performance discussions. However, the evidence is animal evidence, not human performance data.
5. Why ERR activation could have risks
ERRs regulate fundamental metabolic processes in multiple tissues.
Consequently, systemic activation could potentially affect:
Cardiovascular system
ERR signaling is important in cardiac energy metabolism. Long-term pharmacological activation therefore requires cardiovascular investigation.
Liver
ERRs regulate hepatic metabolic programs, so chronic activation could potentially alter lipid and glucose metabolism.
Skeletal muscle
Increasing oxidative metabolism may not necessarily be harmful, but chronic supraphysiological stimulation has not been adequately characterized.
Metabolic homeostasis
The body’s metabolism is highly interconnected. Artificially increasing energy expenditure and changing substrate preference could have effects that are not apparent in short-term animal studies.
These are risk considerations, not proven adverse effects.
6 . SLU-PP-332 is not the same as PPARδ agonists
This distinction is important because some commercial listings incorrectly associate “SLU-PP-322” with PPARδ.
The published SLU-PP-332 compound is an ERR agonist, not a PPARδ agonist.
ERR versus PPARδ
| Feature | SLU-PP-332 | PPARδ agonists |
| Main receptor | ERRα/β/γ | PPARδ |
| Nuclear receptor | Yes | Yes |
| Main metabolic emphasis | Mitochondrial/oxidative program | Lipid metabolism/fat oxidation |
| Exercise-mimetic research | Strong | Also investigated |
| Example compound | SLU-PP-332 | GW501516 |
| Same molecule? | No | No |
Therefore, claims that SLU-PP-322 is a “PPARδ agonist” should be treated cautiously.
7. Relationship to GW501516/Cardarine
This is another common source of confusion.
GW501516 is a PPARδ agonist.
SLU-PP-332 is an ERR agonist.
Both have been investigated in relation to:
- fatty-acid oxidation
- skeletal muscle
- endurance physiology
metabolic disease
but they operate through different nuclear-receptor pathways.
They should not be considered interchangeable compounds.
8. Potential research applications
The scientifically credible applications are primarily experimental.
（1） Mitochondrial biology
Useful for studying regulation of oxidative metabolism.
（2） Exercise physiology
Can help investigate the molecular pathways responsible for endurance adaptation.
（3） Skeletal-muscle metabolism
Useful for studying oxidative muscle-fiber remodeling.
（4）Obesity research
Provides a tool for investigating pharmacological modulation of energy expenditure.
（5）Metabolic syndrome
Potential research tool for studying insulin resistance and altered substrate utilization.
（6）Drug discovery
ERR agonism could potentially serve as a starting point for developing future therapeutics with better selectivity, pharmacokinetics and safety.
Bottom line
SLU-PP-332—not SLU-PP-322—is the scientifically documented compound. It is a synthetic small-molecule ERRα/ERRβ/ERRγ agonist, with somewhat greater activity toward ERRα, developed as an experimental tool for studying exercise-associated metabolic signaling.
Its most interesting property is its ability to activate an ERR-dependent oxidative metabolic program. In mice, this has been associated with:
ERR activation → mitochondrial/oxidative metabolism ↑ → fatty-acid oxidation ↑ → energy expenditure ↑ → oxidative muscle phenotype ↑ → endurance ↑
and, in obese mouse models:
fat accumulation ↓ → glucose tolerance/metabolic parameters improved.
However, the evidence remains preclinical. There is no adequate human evidence establishing its effectiveness, optimal dose, long-term safety, or suitability for weight loss or athletic performance. The distinction between the scientifically characterized SLU-PP-332 and commercially advertised SLU-PP-322 is also critical.
Scientific verdict: high-interest experimental metabolic compound with compelling mouse data, but very low clinical maturity. It should currently be regarded as a research molecule rather than an established human therapeutic or supplement.